Ionis Pharma up after FDA's 'breakthrough therapy' tag for neurological disease drug

Ionis Pharmaceuticals

09/09/2025 14:50

Updates

** Shares of drugmaker Ionis Pharmaceuticals IONS.O up 3.7% at $63.24

** IONS says the U.S. FDA has granted breakthrough therapy designation to its experimental drug, ION582, for the treatment of a rare neurological disease called Angelman syndrome

** AS is a rare genetic disorder that primarily affects the nervous system, characterized by developmental delays, speech impairment, and a happy demeanor

** The FDA's tag is meant to speed up development and review of drugs to treat a serious condition or unmet medical need

** IONS says it began late-stage study for ION582 earlier this year

** Including session moves, stock up 75.1% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))